NYSE:STVNLife Sciences
How Q2 Results and Alina GLP-1 Approvals At Stevanato Group (STVN) Have Changed Its Investment Story
Stevanato Group S.p.A. recently reported past second-quarter 2026 results showing sales rising to €302 million from €280.04 million a year earlier, while net income decreased to €22.96 million and full-year 2026 guidance was slightly narrowed alongside confirming expectations for revenue of about €1.26–€1.28 billion and diluted EPS of €0.53–€0.55.
A few days earlier, liraglutide-based combination products using Stevanato’s proprietary Alina variable-dose pen injector platform received...